Another Avastin biosimilar joins the party as Roche's grip on the market loosens
Avastin has attracted quite the crowd of biosimilars in recent years, and one more pharma company has elbowed its way in.
Regulators on Wednesday …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
